Lenalidomide Teva

Lenalidomide, the active ingredient in Lenalidomide Teva, is an immunomodulatory agent presented as a tablet for oral use. It is indicated for the treatment of multiple myeloma, myelodysplastic syndromes with del(5q) and mantle cell lymphoma in adult patients. As a member of the IMiD class, lenalidomide exerts anti‑angiogenic, immunomodulatory and direct anti‑tumor actions, making it a key component of modern hematologic oncology regimens.

GNH USA supplies Lenalidomide Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide is used in the management of hematologic malignancies, targeting abnormal plasma cells and myeloid clones. - Multiple Myeloma: reduces disease progression and improves survival in patients with relapsed or refractory disease. - Myelodysplastic Syndromes with del(5q): induces transfusion independence and cytogenetic remission in eligible patients. - Mantle Cell Lymphoma: contributes to disease control as part of combination therapy in relapsed or refractory cases.

Lenalidomide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require fluid replacement. - Nausea: feeling of sickness that can be mild to moderate. - Rash: skin irritation or redness. - Constipation: difficulty passing stools. - Peripheral neuropathy: tingling or numbness in extremities.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: markedly reduced white blood cell count increasing infection risk. - Severe thrombocytopenia: low platelet count leading to bleeding. - Secondary primary malignancies: emergence of new cancers. - Hepatotoxicity: liver enzyme elevations or liver injury.

Before initiating lenalidomide therapy, several precautions should be considered to ensure patient safety. - Pregnancy risk: contraindicated in pregnancy (Category X); effective contraception required for women of childbearing potential. - Thromboembolic risk: assess for clotting risk and consider prophylactic anticoagulation. - Hematologic monitoring: perform regular complete blood counts to detect neutropenia or thrombocytopenia. - Renal function: evaluate kidney function and adjust dosing in impairment. - Infection risk: monitor for signs of infection and manage promptly. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Lenalidomide can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers: may reduce lenalidomide exposure; avoid co‑administration. - Anticoagulants (warfarin, DOACs): increased risk of bleeding; close monitoring required.

Moderate Interactions (Monitor Closely): - Immunosuppressants (e.g., cyclosporine): may enhance hematologic toxicity. - Vaccines: live vaccines should be avoided due to immunomodulatory effects. - P-glycoprotein inhibitors: may increase plasma levels of lenalidomide. - NSAIDs: may exacerbate thrombocytopenia risk.